Almirall partners with Centre for Genomic Regulation for advancements in skin cancer
Click Here to Manage Email Alerts
Key takeaways:
- Almirall and the Centre for Genomic Regulation have entered a partnership to advance nonmelanoma skin cancer treatments.
- The partnership will look into evaluating new treatments and drugs.
Almirall and the Centre for Genomic Regulation have entered into a research collaboration to develop and characterize novel preclinical models for the identification of new nonmelanoma skin cancer treatments, according to a press release.
“At Almirall, we regularly identify external collaborations that can leverage and complement our internal capabilities and research,” Karl Ziegelbauer, PhD, chief scientific officer of Almirall SA, said in the release. “This collaboration with [Centre for Genomic Regulation (CGR)] brings us closer to our noble purpose of delivering world-class solutions that make a difference in patients’ lives.”
Two lead investigators from Almirall — Amadeu Gavaldà, PhD, head of pharmacology, and Cristina Gutiérrez, PhD, senior target discovery scientist — will partner with Luciano Di Croce, PhD, group leader at CGR and research professor at Catalan Institution for Research and Advanced Studies in Barcelona, Spain. The researchers will focus their efforts on creating experimental models that will help identify, evaluate and validate new treatments and drugs for nonmelanoma skin cancer.
This partnership with CGR, which came about due to a call for innovative therapies by AlmirallShare, is Almirall’s ninth partnership dedicated to finding new therapies in dermatologic diseases.
Click Here to Manage Email Alerts